Progress in Defining Optimal Treatment Outcome in Schizophrenia

被引:0
|
作者
Gary Remington
George Foussias
Ofer Agid
机构
[1] University of Toronto,Department of Psychiatry, Faculty of Medicine
[2] University of Toronto,Institute of Medical Science
[3] Schizophrenia Program,undefined
[4] Centre for Addiction and Mental Health,undefined
来源
CNS Drugs | 2010年 / 24卷
关键词
Schizophrenia; Clozapine; Negative Symptom; Brief Psychiatric Rate Scale; Symptom Domain;
D O I
暂无
中图分类号
学科分类号
摘要
Historically, schizophrenia has been associated with early-onset, persistent symptoms, and progressive decline accompanied by poor functional recovery. The advent of effective drugs in the 1950s improved symptom control, at least from the standpoint of positive features (e.g. hallucinations, delusions). However, even here the response was limited and efficacy in other symptom domains (cognitive, deficit/negative) was minimal. With clozapine as the prototype, the second-generation antipsychotics arrived in the 1990s with claims of improved tolerability, as well as greater and broader clinical efficacy, all of which was to translate to gains in functional outcome and quality of life. The capacity of these drugs to effect such changes has since been tempered, but it remains that the research and hope generated served as an impetus to redefine outcomes.
引用
收藏
页码:9 / 20
页数:11
相关论文
共 50 条
  • [1] Progress in Defining Optimal Treatment Outcome in Schizophrenia
    Remington, Gary
    Foussias, George
    Agid, Ofer
    CNS DRUGS, 2010, 24 (01) : 9 - 20
  • [2] Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance
    Levine, Stephen Z.
    Rabinowitz, Jonathan
    Uher, Rudolf
    Kapur, Shitij
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 (10) : 1578 - 1585
  • [3] Progress in defining the biological causes of schizophrenia
    Pickard, Benjamin
    EXPERT REVIEWS IN MOLECULAR MEDICINE, 2011, 13 : e25
  • [4] Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders
    Schennach-Wolff, Rebecca
    Jaeger, Markus
    Seemueller, Florian
    Obermeier, Michael
    Messer, Thomas
    Laux, Gerd
    Pfeiffer, Herbert
    Naber, Dieter
    Schmidt, Lutz G.
    Gaebel, Wolfgang
    Huff, Wolfgang
    Heuser, Isabella
    Maier, Wolfgang
    Lemke, Matthias R.
    Ruether, Eckart
    Buchkremer, Gerd
    Gastpar, Markus
    Moeller, Hans-Juergen
    Riedel, Michael
    SCHIZOPHRENIA RESEARCH, 2009, 113 (2-3) : 210 - 217
  • [5] DEFINING TREATMENT REFRACTORINESS IN SCHIZOPHRENIA
    BRENNER, HD
    DENCKER, SJ
    GOLDSTEIN, MJ
    HUBBARD, JW
    KEEGAN, DL
    KRUGER, G
    KULHANEK, F
    LIBERMAN, RP
    MALM, U
    MIDHA, KK
    SCHIZOPHRENIA BULLETIN, 1990, 16 (04) : 551 - 561
  • [6] Defining recovery in schizophrenia: A review of outcome studies
    Ponce-Correa, Felipe
    Caqueo-Urizar, Alejandra
    Berrios, Raul
    Escobar-Soler, Carolang
    PSYCHIATRY RESEARCH, 2023, 322
  • [7] Defining and Achieving Treatment Recovery in Schizophrenia
    Velligan, Dawn I.
    Rao, Sanjai
    JOURNAL OF CLINICAL PSYCHIATRY, 2023, 84 (01)
  • [8] Schizophrenia: Progress in multidisciplinary treatment
    Nunes, Emerson Arcoverde
    REVISTA BRASILEIRA DE PSIQUIATRIA, 2012, 34 (04) : 520 - 520
  • [9] Past, present, and future directions for defining optimal treatment outcome in depression - Remission and beyond
    Keller, MB
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (23): : 3152 - 3160
  • [10] CONCORDANCE OF MULTIPLE ASSESSMENTS OF OUTCOME OF SCHIZOPHRENIA - DEFINING DEPENDENT VARIABLE IN OUTCOME STUDIES
    SCHWARTZ, CC
    MYERS, JK
    ASTRACHAN, BM
    ARCHIVES OF GENERAL PSYCHIATRY, 1975, 32 (10) : 1221 - 1227